Latest news on Alzheimer's

This September 21st, with the initiative "Alzheimer's research has a name and surname", we highlight those people who work daily to bring us closer to our goal of a world without Alzheimer's: our research team

This is the first drug approved by the US regulatory agency through the traditional route that intervenes in the progression of the disease.

The work focuses on the role of pathophysiological processes beyond amyloidosis and tauopathy, and modifiable risk factors in the early development of Alzheimer’s disease during its preclinical stage.

During the meeting, the teams will disseminate the news of their research in the international scientific community.

This is one of the main conclusions of a study led by BBRC and published in Alzheimer’s and Dementia.

The research, based on data from 320 participants of the Alfa cohort, promoted by the ”la Caixa” Foundation, concludes that nutritional interventions could prevent the disease.

The FDA has given the green light to donanemab, a monoclonal antibody that attacks amyloid protein plaques.

The document details the most salient activity of the two centers in 2023, a year marked by a major paradigm shift in the approach to Alzheimer's disease.

The research infrastructure consists of a cohort of nearly 2,700 participants.